---
title: "Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction"
id: "jama-cardiology-12-low-dose-rivaroxaban-to-prevent-left-ventricular-thrombosis-after-anterior-myocardial-infarction"
canonical_url: "https://medichelpline.com/clinical-feed/jama-cardiology-12-low-dose-rivaroxaban-to-prevent-left-ventricular-thrombosis-after-anterior-myocardial-infarction"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "JAMA Cardiology"
source_url: "https://jamanetwork.com/journals/jamacardiology/fullarticle/2845590"
published_at: "2026-04-01T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/jama-cardiology-12-low-dose-rivaroxaban-to-prevent-left-ventricular-thrombosis-after-anterior-myocardial-infarction
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** JAMA Cardiology
- **Source URL:** [Original Journal Publication](https://jamanetwork.com/journals/jamacardiology/fullarticle/2845590)
- **Published At:** 2026-04-01T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
This multicenter randomized clinical trial conducted in France determines whether the addition of low-dose rivaroxaban to dual antiplatelet therapy reduces the incidence of left ventricular thrombus at 1 month in patients with anterior ST-segment elevation myocardial infarction.
## Clinical Analysis & Structured Key Points
JAMA Cardiology published a clinical update in Cardiology on 01 Apr 2026. The item focuses on Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction. Review the original article for the full source wording and details.
## Related Clinical Research

- [Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic.md)
- [NOAC monotherapy vs NOAC+clopidogrel by age in AF patients with drug-eluting stents](https://medichelpline.com/clinical-feed/pubmed-42546025.md) (DOI: 10.1093/ageing/afag224)
- [Post-MI TRPV1 Cardiac Afferent Ablation with RTX Prevents Arrhythmogenic Remodeling](https://medichelpline.com/clinical-feed/biorxiv-7-trpv1-cardiac-afferent-ablation-after-completed-myocardial-infarction-prevents.md)
- [Bayesian Network Meta-Analysis of P2Y12 Inhibitors After ACS: Efficacy, Bleeding, and Uncertainty](https://medichelpline.com/clinical-feed/medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide.md)
- [ESC Quality Indicators for Post-Myocardial Infarction Care: Transition and Chronic Coronary Syndro](https://medichelpline.com/clinical-feed/pubmed-41342498.md) (DOI: 10.1093/eurjpc/zwaf761)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.